663
Participants
Start Date
September 2, 2025
Primary Completion Date
May 30, 2028
Study Completion Date
May 30, 2028
Pasritamig
Pasritamig will be administrated through IV infusion.
Placebo
Placebo will be administrated through IV infusion.
Best Supportive Care (BSC)
BSC will be administered as per physician.
RECRUITING
National Taiwan University Hospital, Taipei
RECRUITING
Taipei Veterans General Hospital, Taipei
RECRUITING
Peter MacCallum Cancer Centre, Melbourne
RECRUITING
Warringal Private Hospital, Heidelberg
RECRUITING
Princess Alexandra Hospital, Woolloongabba
RECRUITING
ICON Cancer Care, Kurralta Park
RECRUITING
Keystone Urology Specialists, Lancaster
RECRUITING
MidLantic Urology, Bala-Cynwyd
RECRUITING
Carolina Urologic Research Center, Myrtle Beach
RECRUITING
Tennessee Oncology, Nashville
RECRUITING
Tennessee Oncology, Chattanooga
RECRUITING
XCancer Omaha / Urology Cancer Center, Omaha
RECRUITING
East Jefferson General Hospital, Metairie
RECRUITING
Colorado Clinical Research, Lakewood
RECRUITING
Oregon Urology Institute, Springfield
RECRUITING
CHU de Quebec Universite Laval, Québec
RECRUITING
Yokohama City University Hospital, Yokohama
RECRUITING
Puerto Rico Medical Research Center, Hato Rey
RECRUITING
Pan American Center for Oncology Trials LLC, Rio Piedras
Janssen Research & Development, LLC
INDUSTRY